COMMUNIQUÉS West-GlobeNewswire

NHS-licensed healthcare platform Evaro partners with period tracking app Clue in UK-first integration
27/10/2025
Partnership bridges the gap between period tracking and contraception access as nearly half of UK women face barriers to contraception care LONDON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Evaro, the NHS-licensed embedded [...]
Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis
27/10/2025
Clinical and Pharmacology Data Presented at ACR Convergence 2025 In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients with [...]
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
27/10/2025
The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation Targeted Glue™ medicinal chemistry technology Amphista’s scientists prospectively [...]
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
27/10/2025
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading [...]
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
27/10/2025
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
27/10/2025
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in [...]
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
27/10/2025
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein [...]
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
27/10/2025
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, [...]
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
27/10/2025
Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate [...]
World's First Multi-Omics LLM, Promising to Decode the Language of Human Biology Showcasing in Global Health Exhibition, Riyadh
27/10/2025
PanOmiQ’s foundational model trained on multi-Omics data breakthrough FPGA-powered deployment addresses data sovereignty challenge, ultrafast AI-driven multi-omics analysis on premises, redefining speed and accuracy in [...]
Citryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025
27/10/2025
CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025 Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical [...]
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
27/10/2025
ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
27/10/2025
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) [...]
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
27/10/2025
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors [...]
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
26/10/2025
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high quality, novel or [...]
New Global Coalition Launches to Address the Hidden Threat of RSV in Adults
26/10/2025
VIENNA, Austria, Oct. 26, 2025 (GLOBE NEWSWIRE) -- A new global coalition, the RSV Alliance, has been launched to raise awareness about the risks of respiratory syncytial virus (RSV) infections, with a focus on aging [...]
MapLight Therapeutics Announces Pricing of Initial Public Offering
26/10/2025
SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous [...]
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
26/10/2025
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by [...]
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
26/10/2025
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning [...]

Pages